"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 2 | 2 | 4 |
| 1997 | 3 | 0 | 3 |
| 1998 | 2 | 0 | 2 |
| 1999 | 1 | 2 | 3 |
| 2000 | 1 | 2 | 3 |
| 2001 | 2 | 2 | 4 |
| 2002 | 1 | 0 | 1 |
| 2003 | 2 | 2 | 4 |
| 2004 | 3 | 3 | 6 |
| 2005 | 0 | 2 | 2 |
| 2006 | 3 | 1 | 4 |
| 2007 | 0 | 1 | 1 |
| 2008 | 2 | 3 | 5 |
| 2009 | 1 | 1 | 2 |
| 2010 | 3 | 2 | 5 |
| 2011 | 8 | 1 | 9 |
| 2012 | 3 | 2 | 5 |
| 2013 | 6 | 3 | 9 |
| 2014 | 5 | 5 | 10 |
| 2015 | 4 | 3 | 7 |
| 2016 | 5 | 3 | 8 |
| 2017 | 1 | 3 | 4 |
| 2018 | 3 | 2 | 5 |
| 2019 | 2 | 2 | 4 |
| 2020 | 4 | 0 | 4 |
| 2022 | 0 | 6 | 6 |
| 2023 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Tamoxifen and the risk of breast cancer in women with a BRCA1 or BRCA2 mutation. Breast Cancer Res Treat. 2023 Sep; 201(2):257-264.
-
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 03 01; 41(7):1376-1382.
-
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 03 01; 41(7):1370-1375.
-
Foxe1 Deletion in the Adult Mouse Is Associated With Increased Thyroidal Mast Cells and Hypothyroidism. Endocrinology. 2022 10 23; 163(12).
-
Optimal breast cancer risk reduction policies tailored to personal risk level. Health Care Manag Sci. 2022 Sep; 25(3):363-388.
-
Selective pressure of endocrine therapy activates the integrated stress response through NF?B signaling in a subpopulation of ER positive breast cancer cells. Breast Cancer Res. 2022 03 09; 24(1):19.
-
In search of autophagy biomarkers in breast cancer: Receptor status and drug agnostic transcriptional changes during autophagy flux in cell lines. PLoS One. 2022; 17(1):e0262134.
-
Hormonal modulation of ESR1 mutant metastasis. Oncogene. 2021 02; 40(5):997-1011.
-
A Randomized Phase IIb Study of Low-dose Tamoxifen in Chest-irradiated Cancer Survivors at Risk for Breast Cancer. Clin Cancer Res. 2021 02 15; 27(4):967-974.
-
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359.